There are currently 81 active clinical trials seeking participants for Hepatocellular Carcinoma research studies. The states with the highest number of trials for Autism participants are California, Guangdong, Texas and New York.
TheraSphere With Durvalumab and Tremelimumab for HCC
NCT05063565
Recruiting
The objective of the ROWAN clinical study is to assess the efficacy of local tumor control in HCC patients who receive TheraSphere followed by durvalumab and tremelimumab.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: University of Arizona- Banner Health, Tucson, Arizona +24 locations
Conditions: Hepatocellular Carcinoma
Register for Updates
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05301842
Recruiting
A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab, tremelimumab and lenvatinib therapy in patients with locoregional hepatocellular carcinoma
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
04/18/2024
Locations: Research Site, Birmingham, Alabama +198 locations
Conditions: Hepatocellular Carcinoma
Register for Updates
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
NCT06084884
Recruiting
A Phase I/II study to evaluate AZD5851 in patients with GPC3+ advanced/recurrent hepatocellular carcinoma.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
04/18/2024
Locations: Research Site, Phoenix, Arizona +15 locations
Conditions: Hepatocellular Carcinoma
Register for Updates
T-Cell Therapy (ECT204) in Adults With Advanced HCC
NCT04864054
Recruiting
This is an open-label, dose escalation, multi-center, Phase I/II clinical trial aimed at assessing the safety and preliminary efficacy of an investigational ARTEMIS® ECT204 T-cell therapy. The trial is suitable for adult subjects (≥ 18 years of age) diagnosed with GPC3-positive HCC, who have failed or not tolerated at least two (2) different anti-HCC systemic agents. Phase I has concluded and a Recommended Phase II Dose (RP2D) has been determined. We are now conducting Phase II to further confi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: City of Hope, Duarte, California +1 locations
Conditions: Hepatocellular Carcinoma, Liver Cancer, Adult, Liver Neoplasm, Metastatic Liver Cancer
Register for Updates
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
NCT04374877
Recruiting
This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of CHS-388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in patients with solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: City of Hope, Duarte, California +20 locations
Conditions: Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
Register for Updates
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
NCT06005740
Recruiting
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: UCLA - JCCC Clinical Research Unit, Los Angeles, California
Conditions: Advanced Solid Tumor, Hepatocellular Carcinoma
Register for Updates
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
NCT04550481
Recruiting
This phase II trial investigates how well lisinopril may work in preventing the progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an accumulation of fatty cells in the liver. NAFLD increases a person's risk of developing liver cancer. Liver fibrosis is the common finding of chronic liver diseases leading to reduced liver function. Lisinopril is a medication that is commonly used to treat high blood pressure. Lisinopril may help to decrease liver fibros... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/13/2024
Locations: Cedars Sinai Medical Center, Los Angeles, California +3 locations
Conditions: Nonalcoholic Steatohepatitis, Hepatocellular Carcinoma
Register for Updates
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
NCT05953337
Recruiting
This is a prospective, multi-center, open-label study to evaluate the effectiveness and safety of Eye90 microspheres® in the treatment of subjects with unresectable Hepatocellular Carcinoma (HCC). Eye90 microspheres is a medical device containing yttrium-90 (Y-90), a radioactive material, and provides local radiation brachytherapy for the treatment of liver tumors.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
04/11/2024
Locations: University of California - Irvine, Orange, California +5 locations
Conditions: Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable, Liver Cancer
Register for Updates
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
NCT05775159
Recruiting
GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: Research Site, Birmingham, Alabama +58 locations
Conditions: Hepatocellular Carcinoma, Biliary Tract Cancer
Register for Updates
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
NCT03937830
Recruiting
Background: Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Most people with advanced HCC survive an average of 6 to 9 months. Researchers are evaluating a combination of treatment drugs to delay the progression of HCC; aiming to help people with HCC live longer. Objective: To study the 6-month progression-free survival in people with advanced HCC treated with bevacizumab, durvalumab, and TACE. Eligibility: Adults ages 18 and older with intermediate or advanced... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/10/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Metastatic Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatocellular Carcinoma
Register for Updates
Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors
NCT05176483
Recruiting
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, PK, preliminary antitumor activity, and effect of biomarkers of XL092 administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) in subjects with advanced solid tumors. In the Expansion Stage, the safety and efficacy of XL092 as monotherapy and in combination therapy will be further evaluated in t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: Exelixis Clinical Site #67, Phoenix, Arizona +121 locations
Conditions: Renal Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer, Urothelial Carcinoma, Solid Tumor, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma
Register for Updates
An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
NCT06342414
Recruiting
It is sometimes difficult to precisely understand whether a primary liver cancer is a hepatocellular carcinoma or a cholangiocarcinoma. The researchers will develop and validate a liquid biopsy, based on exosomal content analysis and powered by machine learning, to help clinicians differentiate these two cancers before surgery.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: City of Hope Medical Center, Duarte, California +4 locations
Conditions: Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma, Primary Liver Cancer, Primary Liver Carcinoma, Hepatic Cancer, Hepatic Carcinoma
Register for Updates